🤩 Wonderful days in 🇵🇱 with new & old friends at PTU national congress! 🙏 for the great hospitality & see you soon Pawel Rajwa Bartosz Malkiewicz wojciech_piotr_krajewski European Association of Urology (EAU) EAU Edu Platform UROONCO EAU Young Academics EAU YAU Prostate Cancer Working Group

Food for thought..... Endometriosis: can metastasize, crazy to call it cancer Gleason 6 (GG1): not a single report ever of metastases without pattern 4 elsewhere (with modern grading), we call it cancer Hmmmm

Extended lymphadenectomy did not improve survival but increased perioperative risks in Muscle-Invasive Bladder Cancer 🟡5-year disease-free survival: Extended 56% vs Standard 60% 🟡Overall survival: E 59% vs S 63% 🟡Mortality within 90 days: Extended 7%, Standard 2% NEJM

Huge news for #ProstateCancer - TALAPRO-2 trial shows sig ⬆️ in OS in all-comers & HRR-mutated pts with 1st-line mCRPC treated with Talazoparib + Enzalutamide (vs Enzalutamide). A major landmark as the 1st trial of a PARPi + ARPi to ⬆️ OS!

Longer follow-up from our landmark ProPSMA study just out European Urology Oncology: PSMA nodal status is prognostic! At 3 years 70% of patients without nodal involvement (N0) disease free, vs. only 46% if N1 CT-defined nodal status is not prognostic. Read the details here:

Gratulacje dla organizatorów 11 Sympozjum Sekcji Urologii Onkologicznej PTU Prof.Roman Sosnowski Pawel Rajwa wojciech_piotr_krajewski . Świetne spotkanie merytoryczne oraz świetni wykładowcy !! Artur Leminski Bartosz Malkiewicz Marcin Słojewski Artur A. Antoniewicz

Insightful interpretation of the RADICALS-HD trial by Alan Dal Pra, MD at yesterday’s PCa masterclass. Kudos to my friends Paolo Gontero, Marco Oderda, Giancarlo Marra, and GiuseppeC. Iorio MD for organizing such a stellar event!

Great insights from Taimur Shah on Karim Touijer’s trial comparing limited vs. extended PLND at yesterday’s #TOP24 prostate cancer masterclass in Turin. Congrats to organizers Paolo Gontero, Marco Oderda, Giancarlo Marra, and GiuseppeC. Iorio MD!

And NOW, TOP 5 PROSTATE CANCER trials of 2024! 1) The ARANOTE trial shows darolutamide + ADT improves rPFS in mHSPC by 46%,--Benefits seen across all subgroups with a favorable safety profile. ⛹🏼‍♂️A new player for doublets in mHSPC! #ESMO24 Dr. Fred Saad silke gillessen

Editor's Choice: Radical Prostatectomy Versus Stereotactic Radiotherapy for Clinically Localised Prostate Cancer: Results of the PACE-A Randomised Trial by Nicholas van As et al Read the full article here: buff.ly/3OSVsu6 Come back to read the Editorial! #UroSoMe #MedTwitter

Conventional imaging understages high-risk nonmetastatic prostate cancer. ☢️PSMA-PET was positive in 84% of cases, detecting M1 disease in 46%, polymetastatic in 24%. #ProstateCancer #PSMAPET #Oncology OncoAlert JAMA Network Open Advanced Prostate Cancer Consensus Conference

Some statistics of the Journal 🌍 Numbers of articles accepted over the past 5 years

5-year (2020-2024) acceptance rate :

Cancer Statistics 2025 are out! #prostatecancer incidence still on the rise, mortality basically flat. Get screened so you can get treatment _when needed_. #pcsm acsjournals.onlinelibrary.wiley.com/doi/epdf/10.33…

#eau25 What is your advice for a 65yo man with Parkinson and 80ml prostate? 💥Functional session: urodynamics first! 💥BPH surgery session: AEEP first! 💥CaP session: what is his PSA? 💥Patient session: LUTS is not so important to me

Micro-ultrasonography-guided biopsy is noninferior to MRI-guided fusion biopsy for the detection of clinically significant prostate cancer in biopsy naïve men. ja.ma/4hzTwTo #EAU25 Julian Struck Moises Socarras Dr. Christopher Fung Arvin K. George, MD JG Pereira

Smarter staging in prostate cancer? 🙋🏼‍♂️🙋🏻‍♂️🙋🏾‍♂️In patients with intermediate/high-risk prostate cancer and negative PSMA PET (miN0), extended pelvic lymph node dissection (ePLND) remains a clinical dilemma. 🔍 This multi-institutional study (n = 282) externally validated five

Histological subtypes/divergent differentiation (HS/DD) in UTUC = worse outcomes. In a review of 14,407 patients, HS/DD linked to higher stage/grade, more LNI/LVI, and worse CSS, OS, RFS. Detection should prompt aggressive tx + close follow-up. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Our new SR and MA published in European Urology Oncology evaluates focal therapy for localized PCa using prospective data only. Important for patient counselling. 📊 50 studies, 4,615 patients 📊 12-mo csPCa RFS in intermediate-risk: 79% (95% CI 74–83%) 🔗 doi.org/10.1016/j.euo.…

Many thanks to my hosts wojciech_piotr_krajewski Bartosz Malkiewicz Jan Łaszkiewicz and the rest of the wonderful Dept of Urology at Wroclaw Medical University observed really cutting edge Endourology and robotics. Also was interviewed by the local TV station as a highlight to my visit.